Strategic Partnerships Position Foghorn Therapeutics as a partner for precision oncology collaborations, highlighting their Gene Traffic Control platform and focus on chromatin regulation to attract biopharma companies seeking novel targets and combo strategies with existing therapies.

Clinical Pipeline Value Leverage the company’s preclinical focus on SMARCA2, CBP/EP300, ARID1B degraders, and ARID1B programs to identify pharma partners interested in de-risked collaboration or licensing opportunities ahead of INDs, especially with oncology and immuno-oncology players.

Financial Readiness With a substantial funding runway and a recent CFO appointment, target sponsors and investors for co-development deals, milestone-heavy partnerships, or strategic investments that align with their growth trajectory and ongoing preclinical data generation.

Strategic Events Engage through upcoming conferences and summits where Foghorn participates (AACR, Guggenheim Biotech Summit, TPD and Induced Proximity Summit) to initiate meeting requests, co-present opportunities, and explore collaboration or licensing conversations around preclinical assets.

Geographic and Facility Strategy Capitalize on the relocation to Watertown with a localized business development plan to attract regional CROs, contract services, and potential co-development hubs, offering proximity advantages to U.S. biotech ecosystems and potential manufacturing or analytics partnerships.